UNIQURE N.V. news, videos and press releases - Page 4
For more news please use our advanced search feature.
UNIQURE N.V. - More news...
UNIQURE N.V. - More news...
- uniQure to Participate in Multiple Upcoming Industry Conferences in April
- uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program
- uniQure Announces 2020 Financial Results and Highlights Recent Company Progress
- uniQure to Participate in Multiple Upcoming Industry Conferences in March
- uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure to Participate in Multiple Upcoming Industry Conferences in February
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
- uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
- uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
- uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
- uniQure to Participate in Multiple Upcoming Industry Conferences in December
- uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
- uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
- uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
- uniQure to Participate in Multiple Upcoming Industry Conferences in November
- uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
- uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure to Participate in Multiple Upcoming Industry Conferences in October
- uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure to Participate in Multiple Upcoming Industry Conferences in September
- uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
- uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
- uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
- uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
- uniQure Announces Change for its 2020 Annual General Meeting of Shareholders
- uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting
- uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress
- uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting
- uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors
